McDermott and Bull executive Search
 

Other News

Kardium Announces First Commercial Procedures with the Globe® Pulsed Field System, the World’s Most Advanced Solution for Atrial Fibrillation

VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium, a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), today announced the successful completion of the first commercial procedures using its integrated mapping and ablation system, the Globe Pulsed Field System, following recent approval from the U.S. Food and Drug Administration (FDA). The […]

Adagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Ventricular Tachycardia

Study Results are Intended to Support PMA Approval of Adagio’s vCLASTM Cryoablation System Designed to Address the Large Population of Patients with Ventricular Arrhythmias LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today […]

Switchback Medical Announces Strategic Investment From TJC and Combination With LightningCath and Proto Lase

NEW YORK–(BUSINESS WIRE)–Switchback Medical, LLC is pleased to announce a strategic investment from an affiliate of TJC, L.P. (“TJC”), a private investment firm. Switchback Medical, LLC has combined into a single platform with its affiliates LightningCath, Inc. and Proto Lase, Inc. (together, “Switchback” or the “Company”), with the businesses’ founders […]

Relief Cardiovascular Announces First-in-Human Procedures with World’s First Transcatheter Smart Implant for the Treatment of Congestion in Heart Failure

IRVINE, Calif., Sept. 30, 2025 /PRNewswire/ — Relief Cardiovascular, a private company developing transcatheter smart implants to transform the treatment of heart failure, today announced the successful first-in-human use of the Relief System – the world’s first implant designed to both hemodynamically monitor and treat congestion in heart failure. The breakthrough procedures were […]

Former Founding Director of the NIH Center for Interventional Oncology & Chief of Interventional Radiology, Dr. Bradford Wood, MD joins DeepSight as Vice President of Strategic Partnerships

SANTA CLARA, Calif., Oct. 1, 2025 /PRNewswire/ — DeepSight Technology, a leader in advanced interventional ultrasound solutions, is proud to announce the appointment of Bradford Wood, MD, formerly of the National Institutes of Health (NIH), as Vice President of Strategic Partnerships. Dr….

Elixir Medical Announces Key Commercial Milestone With LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL)

LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques New clinical study to be presented at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco, CA, on October 27, 2025 MILPITAS, Calif. , Oct. 01, 2025 (GLOBE NEWSWIRE) — Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced key milestone and full market release of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL), following the announcement of CE Mark approval earlier this year. The LithiX HC-IVL System is an advanced intravascular lithotripsy technology designed to optimize device expansion in calcified coronary artery blockages during an angioplasty procedure. Unlike energy-based systems with a more complex workflow requiring additional equipment, the LithiX device is a highly deliverable balloon-based system with integrated low-profile metallic hemispheres to create focal pressure amplification based on Hertz Contact Stress principle. The Hertz Contact Lithotripsy hemispheres work selectively on calcium within the target lesion, breaking apart and fragmenting the hardened plaque under low balloon inflation pressure. The hemispheres create multiple highly localized points of contact force to create deep and wide fractures while sparing the adjacent non-calcified vessel tissue. Following CE Mark announcement and limited market release in early April, the LithiX HC-IVL technology has achieved key milestones highlighted by positive market reception and physician adoption: Over 400 patients have been treated with LithiX HC-IVL across 16 countries in Europe and AsiaLithiX has been evaluated and is being adopted in over 90 leading hospitals During the initial phase of the LithiX HC-IVL launch, physicians consistently highlighted several important performance attributes: High deliverability of the device allowing for treatment of tortuous coronary anatomies Success in treating a broad range of calcified plaque morphologies such as eccentric, nodular and concentric calcium, enabling excellent final lesion expansion Versatility and streamlined workflow translating to low resource utilization “LithiX quickly became our primary calcium modification tool. As a high-volume center, we value its effectiveness and versatility enabling us to treat the most complex calcified lesions in patients with advanced heart disease, as well as its cost effectiveness in our practice through reduced use of additional calcium modification devices and a simpler procedure flow,” said Dr. Tamil Selvan Muthusamy of Cardiac Vascular Sentral Kuala Lumpur (CVSKL) Hospital, Kuala Lumpur, Malaysia. Additionally, Elixir announced that CVSKL Hospital has conducted an investigator-initiated study of one hundred patients treated with LithiX HC-IVL. The results, including analysis with intravascular imaging, will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco, CA, on October 27 in the Innovation Session. TCT is the world’s leading educational forum specializing in interventional cardiovascular medicine and clinical science. The successful completion of the limited market release enables Elixir Medical to continue expansion of LithiX HC-IVL into global markets.  About Elixir Medical Elixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Elixir Medical was named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025 and Fierce Medtech’s 2025 Fierce 15 list. Visit us at www.elixirmedical.com and on LinkedIn and X. The LithiX HC-IVL System is CE Mark approved. Not available in the United States. Media Contact Richard LaermerRLM PRelixir@rlmpr.com(212) 741-5106 X 216

CorVista Health Appoints Guido Neels and Dino Trevisani to Board of Directors

Veteran MedTech leader Guido Neels joins CorVista, leveraging his experience as EW Healthcare Partners Operating Partner and former Guidant COO.Company founder Dino Trevisani returns to CorVista, bringing decades of global technology expertise from his tenure as IBM Canada’s President and General Manager.The additions come at a pivotal moment as CorVista accelerates toward commercial expansion and broad clinical adoption. BETHESDA, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) — CorVista Health, Inc., a digital health company dedicated to transforming the diagnosis of cardiovascular disease, today announced the appointment of Guido Neels and Dino Trevisani to its Board of Directors. Mr. Neels brings more than four decades of experience in global healthcare leadership and investment. He currently serves as Operating Partner at EW Healthcare Partners and was formerly Chief Operating Officer of Guidant Corporation. At EW, he has played a central role in building and leading the firm’s medical device investment practice. Since joining EW in 2006, Mr. Neels has guided multiple growth-stage companies, and he currently serves on the Boards of Enercon Technologies, Bioventus (both EW Healthcare Partners portfolio companies), and Impulse Dynamics. Previously, as COO of Guidant Corporation, he played a pivotal role in building one of the world’s leading interventional cardiology companies, culminating in Guidant’s $27B acquisition by Boston Scientific – one of the largest transactions in medtech history. During that time, he oversaw operations across four global divisions: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions while also leading multiple corporate functions, including sales operations, corporate communications, marketing, investor relations, and government relations. Earlier in his career, Mr. Neels held general management, sales, and marketing leadership roles at Eli Lilly & Company in the U.S. and Europe. “Guido’s decision to join our Board is a strong validation of CorVista’s mission and momentum, and his deep expertise in scaling medtech companies and in venture capital will be invaluable to both our leadership team and the company,” said Adrian Lam, Chief Executive Officer of CorVista Health. “His leadership experience at Guidant and his strategic perspective from decades of investing will strengthen our team as we enter our next phase of growth and scale commercially.” Mr. Neels holds a Business Engineering degree from the University of Leuven in Belgium and a Master of Business Administration degree from Stanford University. Mr. Trevisani is the original founder of CorVista, and brings extensive global technology expertise. Notably, he spent 36 years at IBM where he held multiple senior leadership roles, including serving as President and General Manager of IBM Canada, Global Managing Director of Technology, and General Manager of Financial Services for IBM North America. He currently serves as Chief Growth Officer at Unqork. Unqork is the leader in Regenerative Applications and the future of AI enterprise application development. Unqork is built on data driven architecture and entirely separates the logic from code. Mr. Trevisani also serves as an advisor to Tata Communications, one of the world’s leading global digital ecosystem enablers and telecommunications companies, and part of the Tata Group. Mr. Trevisani holds a Bachelor’s Degree in Commerce and Business from McMaster University, an MBA in Accounting and Finance from Cornell University, and an MBA from Queen’s University. In addition to his corporate leadership, he is also a Co-founder of CorVista Health. “Dino’s exceptional track record of driving growth and innovation across the technology and financial services sectors, coupled with his early role in CorVista’s founding, brings invaluable perspective to our Board,” said Tim Attebery, Chairman of the CorVista Health Board of Directors. “Having one of our original founders return at this pivotal stage is a powerful validation of the company’s trajectory and the clear opportunities ahead. His experience scaling global organizations and advancing transformative technologies will be invaluable as CorVista enters its next phase of commercial growth and seeks to accelerate its impact on global cardiovascular care.” “I have spent my career helping advance medical innovation, and CorVista represents one of the most exciting opportunities I have seen. The company is addressing one of the most pressing challenges in cardiovascular disease and has a differentiated strategy and approach to tackle this problem,” said Guido Neels. “As one of the first companies to bring AI to healthcare, CorVista’s innovative diagnostic platform has the potential to change how and where patients are diagnosed, eliminating delays that often are detrimental for patients. I look forward to contributing my experience to support the company’s next phase of growth and impact on global health.” “Having been part of CorVista Health’s founding, I’m thrilled to return to the Board at this defining moment for the company,” said Dino Trevisani. “CorVista’s technology has the power to transform how cardiovascular disease is diagnosed and managed, bringing faster, more accessible insights to physicians and patients when they matter most. The company has made tremendous strides in advancing its platform and readiness for commercialization, and I’m eager to help guide this next phase of growth, innovation, and impact on global heart health.” About CorVista Health CorVista Health is on a mission to transform cardiovascular care with diagnostics that shorten the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. We are dedicated to enabling more equitable care by providing access to immediately actionable, high-quality cardiovascular test results for previously underserved patient populations – with the goal of contributing to a future where everyone has timely access to life-saving cardiovascular care. For more information, please visit www.corvista.com. Media Contact:media@corvista.com

SpectraWAVE Appoints Dr. Jonathan Hill, MD as Chief Medical Officer

— Interventional cardiologist with extensive clinical study experience and expertise in intravascular imaging, physiology, and complex PCI to guide worldwide clinical strategy — BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced the appointment of […]

FIRE1’s Norm System Congestion Score Featured as Late-Breaking Science at HFSA 2025

DUBLIN–(BUSINESS WIRE)–FIRE1, a connected medical device solutions company, announced that its program of trials (FUTURE-HF and FUTURE-HF2) were selected for presentation in the Late-Breaking Science program at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The plenary session took place place on Sunday, September 28, from 9:00 – 10:30 a.m. CT. […]

UnitedHealthcare and Cigna Coverage for Cleerly LABS Advanced Plaque Analysis Begins October 1st

DENVER–(BUSINESS WIRE)–Cleerly, the leader in AI-based advanced cardiovascular imaging, today announced that groundbreaking coverage policies from UnitedHealthcare and Cigna for Cleerly® LABS™ advanced plaque analysis will go into effect on October 1st, 2025. These landmark decisions mark a new era in cardiac care, bringing AI-guided quantitative coronary CT angiography (AI-QCT)/Coronary […]